Summary
Bristol Myers Squibb (BMY) has filed an 8-K report on April 29, 2022, detailing their financial results for the first quarter of 2022. The report primarily serves to furnish the company's earnings press release and supplemental financial information, which were made public on the same date. Investors should note that this filing is informational, providing access to the detailed Q1 2022 financial performance and operational updates presented by the company. The filing incorporates by reference the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2) which contain the core financial data. Additionally, a presentation (Exhibit 99.3) shared during the Q1 2022 earnings call is included, offering insights into financial and operating initiatives. While the presentation includes non-GAAP financial measures, reconciliations to GAAP are available in the supplemental information.
Key Highlights
- 1BMY announced its first quarter 2022 financial results on April 29, 2022.
- 2The 8-K filing furnishes the company's Q1 2022 Earnings Press Release (Exhibit 99.1).
- 3Supplemental financial information (Exhibit 99.2) is also provided for investors.
- 4A presentation on financial and operating initiatives (Exhibit 99.3) from the Q1 2022 earnings call is available.
- 5The filing includes references to non-GAAP financial information, with reconciliations provided in the supplemental materials.
- 6Information furnished under Item 7.01 is not considered 'filed' for certain regulatory purposes.